Analyst Price Target is $11.43
▲ +122.35% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Amylyx Pharmaceuticals in the last 3 months. The average price target is $11.43, with a high forecast of $36.00 and a low forecast of $3.00. The average price target represents a 122.35% upside from the last price of $5.14.
Current Consensus is
Moderate Buy
The current consensus among 10 polled investment analysts is to moderate buy stock in Amylyx Pharmaceuticals. This rating changed within the last month from a Hold consensus rating.
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More